Institution Directory

Clinical trials at City of Hope

Sites in Duarte, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1040

Shown on this page

Current sort

Live official records

Conditions: Advanced Solid Tumors
Interventions: FID-022; Drug
Lead sponsor: Fulgent Pharma LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Tampa, Florida

Conditions: Ewing Sarcoma, Colorectal Adenocarcinoma
Interventions: INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 24
States / cities: Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more

Conditions: Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 17
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 13 more

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Interventions: IMGN632; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 13 more

Conditions: Solid Tumors
Interventions: ORIC-114, Chemotherapy drug; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 14 more

Conditions: Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 34
States / cities: Buena Park, California • Duarte, California • Irvine, California + 27 more

Conditions: Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
Interventions: IV ICT01; Biological
Lead sponsor: ImCheck Therapeutics, an Ipsen company; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Gilbert, Arizona • Duarte, California • New Haven, Connecticut + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 31
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: AB-3028; Biological
Lead sponsor: Arsenal Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 6 more

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Advanced Liver Cancers
Interventions: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Duarte, California • Orange, California + 11 more

Conditions: AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Interventions: OM336; Drug
Lead sponsor: Lakefront Biotherapeutics West LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more

About this City of Hope institution page

What this page lists: ClinicalTrials.gov records that list City of Hope in Duarte, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at City of Hope

Filter and sort this campus

Live official records

Study of FID-022 in Participants With Advanced Solid Tumors

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

First-in-Human Study of ICT01 in Patients With Advanced Cancer

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

OM336 in Autoimmune Cytopenias

About this City of Hope institution page